Cardiac involvement with mycosis fungoides: Could this explain alemtuzumab toxicity?

Leukemia and Lymphoma

Volumn 49, Issue 10, 2008, Pages 2022-2024

  Sleigh, Kerry Ann ^a   Smith, Mark E F ^a   Rule, Simon A J ^a  

^a DERRIFORD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CD3 ANTIGEN; CD4 ANTIGEN; STEROID;

AGED; BRADYCARDIA; CASE REPORT; CONFERENCE PAPER; DIZZINESS; DRUG INTERMITTENT THERAPY; DYSPNEA; ECZEMA; FATALITY; FEMALE; FIRST DEGREE ATRIOVENTRICULAR BLOCK; HEART MUSCLE BIOPSY; HUMAN; HYPOTENSION; IMMUNOHISTOCHEMISTRY; LETHARGY; LYMPHOCYTIC INFILTRATION; MALAISE; MYCOSIS FUNGOIDES; PRIORITY JOURNAL; PUVA; SKIN BIOPSY; SKIN ULCER; T CELL LYMPHOMA; T WAVE INVERSION; THORAX PAIN; WEAKNESS;

AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; FEMALE; HEART NEOPLASMS; HUMANS; MYCOSIS FUNGOIDES; NEOPLASM INVASIVENESS;

EID: 55049112112     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190801910920     Document Type: Conference Paper

References (17)

1. Willemze, R., Jaffe, E. F., Burg, G., Cerroni, L., Berti, E. Swerdlow, S. H. et al. (2005) WHO-EORTC classification for cutaneous lymphomas. Blood, 105, pp. 3768-3785.
2. Roberts, W. C., Glancy, D. L. and DeVita, V. T. (1968) Heart in malignant lymphoma (Hodgkin's disease, lymphosarcoma, reticulum cell sarcoma and mycosis fungoides) a study of 196 autopsy cases. Am J Cardiol, 22, pp. 85-107.
3. Youn, H. K., Lui, H. L., Mraz-Gerhard, S., Varghese, A. and Hoppe, R. T. (2003) Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome. Arch Dermatol, 139, pp. 857-866.
4. Enblad, G., Hagberg, H., Erlanson, M., Lundin, J., Porwit MacDonald, A Repp, R. et al. (2004) A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood, 103, pp. 2920-2924.
5. Saricaoglu, H., Tunali, S, Özkalemkas, F., Ali, R., Bülbül, E. Aydoǧan, K. et al. (2000) Mycosis fungoides with central nervous system involvement. Int J Dermatol, 39, pp. 874-875.
6. Lippert, B. M., Höft, S., Teymoortash, A., Wiedow, O., Rovert, J. and Werner, J. A. (2002) Mycosis fungoides of the larynx: Case report and review of the literature. Otolarygol Polska, 6, pp. 661-667.
7. Carpio-O'Donovan, R. and Freeman, C. (2002) Brainstem involvement with mycosis fungoides: An unusual central nervous system complication. Am J Neuroradiol, 23, pp. 533-534.
8. MacGee, W. (1991) Metastatic and invasive tumours involving the heart in a geriatric population: A necropsy study. Vichows Archiv A Pathol Anat Histopathol, 419, pp. 183-189.
9. Cooper, D. L., Sinard, J. H., Edelson, R. L. and Flynn, S. D. (1994) Cardiogenic shock due to progression of cutaneous T-cell lymphoma. South Med J, 87, pp. 89-94.
10. Lenihan, D. J., Alencar, A. J., Yang, D., Kurzrock, R., Keating, M. R. and Duvic, M. (2004) Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sezary syndrome. Blood, 104, pp. 655-658.
11. Cersosimo, R. J. (2003) Monoclonal antibodies in the treatment of cancer: Part 2. Am J Health Syst Pharm, 60, pp. 1631-1641.
12. Ravandi, F. and O'Brien, S. (2006) Alemtuzumab in CLL and other lymphoid neoplasms. Cancer Invest, 24, pp. 718-725.
13. Lundin, J., Kennedy, B., Dearden, C., Dyer, M JS and Österborg, A. (2005) No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sezary syndrome. Blood, 105, pp. 4148-4149.
14. Kennedy, G. A., Seymour, J. F., Wolf, M., Januszewicz, H., Davison, J. McCormack, C. et al. (2003) Treatment of patients with advanced mycosis fungoides and Sezary syndrome with alemtuzumab. Eur J Haematol, 71, pp. 250-256.
15. Basquira, A. L., Beretta, A. R., Garcia, J. J. and Palazzo, E. D. (2004) Coronary ischaemia related to alemtuzumab therapy. Ann Oncol, 15, pp. 539-540.
16. Swaminathan, A., Tzamaloukas, A. H., Clark, D. A., McLemore, J. L., McKinney, D. R. and Crooks, L. A. (2002) Oliguric acute renal failure in mycosis fungoides with lymphomatous infiltrates in the kidneys. Int Urol Nephrol, 33, pp. 149-155.
17. Lundin, J., Hogberg, H., Repp, R., Cavallin-Ståhl, E., Freden, S. Juliusson, G. et al. (2003) Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood, 101, pp. 4267-4272.